TGFB1 and colon carcinoma: Finally, the authors showed that inhibition of thrombin using dabigatran etexilate (a competitive and reversible direct thrombin inhibitor approved for venous thromboembolic events) reduced the GARP-dependent production of TGF-β from platelets, blocked TGF-β deposition in both the tumor bed and the stroma of colon carcinoma [65] and allowed the increase of CD8 T cells [66], NK cells [64] and neutrophils [67] in the TME [65].